The present study was undertaken to elucidate (1) the relationship between plasma concentration of medroxyprogesterone acetate (MPA; Clinovir) administered by the PO and the IM routes; and (2) the relationship between dose and plasma concentration of MPA. Nineteen patients entered the study. In each patient the plasma concentration was monitored after a single PO and IM administration of MPA at the following dose levels: 100 mg (5 patients), 400 mg (5 patients), 800 mg (5 patients) and 1,200 mg (4 patients). The time interval between PO and the IM administration was 1 week. The results show (1) a very large interindividual variation in plasma concentration; (2) increasing plasma concentration with both PO and IM dose; (3) after the IM administration plasma levels are steady or increase slightly within the test period; (4) after the oral administration the concentration increases rapidly to reach a peak before 2-7 h and subsequently decreases again, peak concentrations being 2-10 times higher than after IM administration; and (5) within the test periods the plasma concentration x time (0-168 h) is comparable with the two methods of administration.
This paper reviews the theoretical background for its few adverse side effects. Furthermore, the overall the use of progestins in advanced breast cancer and the dinical experience obtained from 13 major studies.The average rate of response is about 30%, with somewhat higher rates when the dominant site of disease is local-response rate for Tamoxifen-treated patients with advanced breast cancer has been found to lie between 30 and 45"70 (273 329 38* 54).
Acta Obstet Gynecol Scand Suppl I01
SummaryIn order to establish the optimal dose of tamoxifen in the treatment of advanced breast cancer in postmenopausal women, a randomized trial comparing 90 mg daily with the currently recommended dose of 30 mg daily was conducted. Sixty-eight patients were treated with the high dose and 75 patients with the low dose. The rate of response was 36 and 37~ (p = 0.74), respectively. The time to response, duration of response, and the time to treatment failure were also identical at the two dose levels. Only a few side effects were observed, and they were equally distributed among the two treatment groups. It is concluded that a 30 mg daily dose of tamoxifen seems to be as effective as 90 mg.
The present study was undertaken to elucidate: 1) The relationship between plasma concentration of medroxyprogesterone-acetate (MPA, ClinovirR, Depo-Provera, Upjohn) administered both orally and intramuscularly. 2) The relation between dose and plasma concentration of MPA.Nineteen patients entered the study. In each patient the plasma concentration was monitored after the administration of a single oral and one intramuscular dose of MPA at the following dosage levels: 100 mg (5 patients), 400 mg (5 patients), 800 mg (5 patients) and 1 200 mg (4 patients). The interval between the oral and i.m. administration was 1 week.The results show: 1) A very large interindividual variation in plasma concentration. 2) An increase in plasma concentration after both oral and i.m. dose. 3) After the i.m. administration, plasma levels remained steady or increased slightly throughout the test period. 4) After the oral administration the concentration increased rapidly to reach a peak by 2-7 hours, subsequently decreasing. Peak concentrations were 2-10 times higher than after i.m. administration. 5 ) Over the test period, the plasma concentration x time (0-168 h) is similar in the two modes of administration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.